ArticleGenes & cancer2010
Sanguinarine suppresses prostate tumor growth and inhibits survivin expression.
Article in Genes & cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Phytochemicals in Inhibition of Prostate Cancer: Evidence from Molecular Mechanisms Studies.Biomolecules · 2022Pooled it
- Targeting Prostate Cancer Cells Using Anti-Sortilin and Anti-Syndecan-1 Antibody Drug Conjugates.International journal of molecular sciences · 2025Article
- Cicer arietinum extract as antitumor and protective agent against Ehrlich Solid Carcinoma-bearing mice.BMC complementary medicine and therapies · 2025Article
- Incredible use of plant-derived bioactives as anticancer agents.RSC advances · 2025Review
- The Anticancer Effect of Natural Plant Alkaloid Isoquinolines.International journal of molecular sciences · 2021Review
- Mining Natural Products with Anticancer Biological Activity through a Systems Biology Approach.Oxidative medicine and cellular longevity · 2021Article
- Sanguinarine Induces Apoptosis in Papillary Thyroid Cancer Cells via Generation of Reactive Oxygen Species.Molecules (Basel, Switzerland) · 2020Article
- IGFBP-3 Is the Key Target of Sanguinarine in Promoting Apoptosis in Hepatocellular Carcinoma.Cancer management and research · 2020Article
- Apoptotic Activities ofIntegrative medicine (Encinitas, Calif.) · 2018Article
- Sanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway.Journal of cellular and molecular medicine · 2017Article
- New use of an old drug: inhibition of breast cancer stem cells by benztropine mesylate.Oncotarget · 2017Article
- Anti-inflammatory and neuroprotective effects of sanguinarine following cerebral ischemia in rats.Experimental and therapeutic medicine · 2017Article
- Breaking a pathogen's iron will: Inhibiting siderophore production as an antimicrobial strategy.Biochimica et biophysica acta · 2015Review
- YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network.Oncotarget · 2015Article
- Molecular signatures of sanguinarine in human pancreatic cancer cells: A large scale label-free comparative proteomics approach.Oncotarget · 2015Article
- Owners' perception of the efficacy of Newmarket bloodroot ointment in treating equine sarcoids.The Canadian veterinary journal = La revue veterinaire canadienne · 2014Article
- Targets and candidate agents for type 2 diabetes treatment with computational bioinformatics approach.Journal of diabetes research · 2014Article
- Identification of plumbagin and sanguinarine as effective chemotherapeutic agents for treatment of schistosomiasis.International journal for parasitology. Drugs and drug resistance · 2013Article
- Sanguinarine inhibits vascular endothelial growth factor release by generation of reactive oxygen species in MCF-7 human mammary adenocarcinoma cells.BioMed research international · 2013Article
- Progress of molecular targeted therapies for prostate cancers.Biochimica et biophysica acta · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Prostate cancer is a frequently occurring disease and is the second leading cause of cancer-related deaths of men in the United States. Current treatments have proved inadequate in curing or controlling prostate cancer, and a search for agents for the management of this disease is urgently needed. Survivin plays an important role in both progression of castration-resistant prostate cancer and resistance to chemotherapy. Altered expression of survivin in prostate cancer cells is associated with cancer progression, drug/radiation resistance, poor prognosis, and short patient survival. In the present study, the authors performed a cell-based rapid screen of the Prestwick Chemical Library consisting of 1120 Food and Drug Administration-approved compounds with known safety and bioavailability in humans to identify potential inhibitors of survivin and anticancer agents for prostate cancer. Sanguinarine, a benzophenanthridine alkaloid derived primarily from the bloodroot plant, was identified as a novel inhibitor of survivin that selectively kills prostate cancer cells over "normal" prostate epithelial cells. The authors found that sanguinarine inhibits survivin protein expression through protein degradation via the ubiquitin-proteasome system. Sanguinarine induces apoptosis and inhibits growth of human prostate cancer cells and in vivo tumor formation. Administration of sanguinarine, beginning 3 days after ectopic implantation of DU145 human prostate cancer cells, reduces both tumor weight and volume. In addition, sanguinarine sensitized paclitaxel-mediated growth inhibition and apoptosis, offering a potential therapeutic strategy for overcoming taxol resistance. These results suggest that sanguinarine may be developed as an agent either alone or in combination with taxol for treatment of prostate cancer overexpressing survivin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.